Systemic lupus erythematosus (SLE) is the most common disease associated with antiphospholipid syndrome (APS). We, therefore, evaluated 46 patients with refractory SLE treated by autologous hematopoietic stem cell transplantation (HSCT) for a history of pre-transplant APS. The prevalence of SLE-related APS in our patient population was 61% (28 out of 46 patients with refractory SLE). Nineteen of 28 patients with APS had lupus anticoagulant (LA) and /or high titers of anticardiolipin antibodies (ACLA), either IgG and/or IgM, when evaluated at study entry. Six of eight evaluable LA-positive patients became and remained LA-negative; five of seven initially ACLA IgG-positive patients and nine of eleven ACLA IgM-positive patients demonstrated normalization of ACLA titers when followed after HSCT. Eighteen out of 22 patients refractory to chronic anticoagulation discontinued anticoagulation therapy a median of 4 months posttransplant; 78% of them remained thrombotic event-free and in complete SLE remission for up to 78 months (median 15 months) after HSCT. There was no treatment-related mortality. Autologous HSCT may be performed safely in patients with APS and appears to be effective therapy for eliminating ALPA and preventing thrombotic complications in SLE patients.
Introduction
APS is defined by the Sapporo criteria as the presence of antiphospholipid antibodies (APLA), either lupus anticoagulant (LA) or anticardiolipin antibodies (ACLA), and occurrence of either an acute thromboembolic event or fetal wastage. 1, 2 APS-related thrombotic events may be venous or arterial while APS-related fetal morbidity includes premature births, spontaneous abortions, and fetal death. Other manifestations associated with APS but not part of the Sapporo criteria for definite APS include thrombocytopenia, hemolytic anemia, cardiac valve disease (Libman-Sacks endocarditis (LSE), livedo reticularis (LR) and various neurologic manifestations including intractable headaches, migraines, seizures, chorea, transient ischemic attacks (TIA), cerebrovascular accidents (CVA), amaurosis fugax, dementia, psychosis, depression, transverse myelitis, and a multiple sclerosis-like disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] With the exception of anticoagulation, there is no standard therapy for APS. Current therapy for APS-related thrombosis is life-long anticoagulation with warfarin adjusted for an international normalization ratio (INR) greater than 2.0-3.0 to reduce the risk of recurrent thrombi despite the potential for serious bleeding complications. [16] [17] [18] [19] [20] [21] Some studies suggest there might be no significant protection against future APS-related thromboembolic events even with warfarin and/or aspirin anticoagulation. 22, 23 APS is classified into primary and secondary, the latter being associated with connective tissue disease. SLE is the most common cause of secondary APS, and the prevalence of APLA, either LA or ACLA, in patients with SLE is reported to be as high as 30 to 50%. [24] [25] [26] [27] [28] [29] Recently, a new approach to treating severe and refractory SLE with high-dose chemotherapy and autologous HSCT has been reported to induce remission of active SLE. [30] [31] [32] [33] [34] [35] We analyzed 46 patients with severe and refractory SLE treated by high-dose chemotherapy and autologous HSCT at Northwestern University with the objective to determine the prevalence of APS, the effect of this therapy on APLA positivity, recurrent thrombotic rates, and changes in APS-related clinical manifestations. 
SLE disease activity
Remission of SLE is defined according to Responder Index for Lupus Erythematosus (RIFLE) criteria as requiring no immune suppressive medications except physiologic doses of corticosteroids, i.e. 10 mg or less of prednisone or corticosteroid equivalent per day. 36 Antiphospholipid syndrome APS according to the Sapporo criteria is defined by one clinical criteria of either vascular thrombosis or fetal morbidity and one immunological criteria of either LA or ACLA (termed definite APS). 1 
Stem cell mobilization and conditioning regimen
Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 gm/m 2 ) and granulocyte colony-stimulating factor (G-CSF) at 5mcg/kg/day administered subcutaneously daily beginning 3 days later. Leukapheresis was initiated when white blood cell count reached 1.0x10 9 /liter and continued daily until the number of stem cells exceeded 1.4 x 10 6 CD34 + cells/kg after positive selection using Isolex (Nexell, Irvine, CA) or Ceprate (Cellpro, Bothell, WA) stem cell concentrator. The conditioning regimen consisted of cyclophosphamide 50mg/kg/day intravenously (IV) on days -5, -4, -3, -2
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Antibiotic prophylaxis
Prophylactic antibiotic regimen included aerosolized pentamidine (300mg) once the day on admission, fluoroquinolone (ciprofloxacin or levofloxacin) changed to IV cefepime upon neutropenia, fluconazole or voriconazole, and acyclovir or valacyclovir daily. G-CSF (5 mcg/kg/day) injections were started on day 0 (day of stem cell infusion) and continued until the resolution of neutropenia (absolute neutrophil count > 1,000/mcL).
Patients
continued to take prophylactic monthly pentamidine or sulfamethoxazole/trimethoprine three times per week, daily diflucan or voriconazole for 6 months, and daily acyclovir or valacyclovir twice a day for a year after the transplant.
Anticoagulation prophylaxis
One to two weeks prior to admission, warfarin anticoagulation was discontinued and therapeutic anticoagulation initiated with either subcutaneous lovenox 1.0 mg/kg every 12 hours (reduced to once a day for creatinine clearance <30cc/hr) or subcutaneous fragmin 200 units/kg/day (reduced to 100 units/kg/day for creatinine clearance < 30 cc/hr). After the conditioning regimen when platelet counts fell below 50,000/ml, low molecular weight heparin (LMWH) was adjusted for prophylaxis dose of either 40mg/kg/day of lovenox or 5000 units/day of fragmin.
Blood transfusions
Platelet transfusions were given to maintain platelet counts > 20,000/ul to 30,000/ul.
Packed red blood cells (PRBC) were transfused for hemoglobin < 8.0 g/dl. Platelets and PRBC were irradiated, cytomegalovirus safe, and leukocyte depleted.
Post-transplant follow-up
After HSCT, patients visited transplant physician at NMH, Chicago, for scheduled follow-ups at 3, 6, 12 months and then yearly thereafter. History, physical examination, serological testing and necessary imaging studies were performed during follow-up visits.
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Statistical analysis
Kendall's Tau coefficient of concordance was utilized for analysis of relationship between non-parametrical variables such as post-HSCT relapsed versus negative APLA, thrombotic events, associated APS features, and active SLE using Statistica software (Tulsa, OK, USA).
Results

Patient profile
Forty six patients underwent autologous HSCT for SLE. This paper is restricted to the 28 patients (61%) with APS: twenty patients (44%) who fulfilled Sapporo criteria for definite APS, and eight patients (17%) who did not meet Sapporo criteria but demonstrated APLA positivity with other APS associated manifestations such as thrombocytopenia, hemolytic anemia, cardiac valve disease, or dermatologic or neurologic manifestations ("probable APS" group) ( Table 1) . One patient (2%) was APLA (ACLA IgG) positive but had no history of thrombosis or manifestations related to APS and is not discussed further. Of 28 patients with APS, 25 (89%) were female, and their mean age was 29 (range 16 to 52) years old. The indications for HSCT in patients with APS included nephritis (18 patients), CNS disease such as cerebritis / myelitis (20 patients), pulmonary involvement including pneumonitis / alveolar hemorrhage / shrinking lung syndrome (8 patients), cutaneous vasculitis (9 patients), autoimmune hemolytic anemia (3 patients), immune thrombocytopenic purpura (3 patients), autoimmune hepatitis (1 patient), and myocarditis (1 patient). Two patients were eligible for HSCT only due to refractory APS. One patient, despite warfarin and aspirin anticoagulation, had recurrent arterial and venous thrombi including two myocardial infarctions, two cerebral infarcts, two deep venous thromboses, and pulmonary emboli.
The second patient experienced pulmonary embolism twice, suffered from CVA with 
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Definite APS
Twenty patients of a total 46 SLE patients who underwent HSCT met Sapporo criteria for definite APS (44%) ( Table 1 ). The mean age and sex ratio of those patients meeting 
Probable APS
Eight patients with positive APLA, either LA or ACLA, and associated APS symptoms did not meet Sapporo criteria for definite APS, but for the purpose of this summary, were classified as having a "probable APS" (Table 1) . APS manifestations within this group included LR (1), LSE (1), thrombocytopenia (1), myelitis / transverse myelitis (3), intractable headache (1), seizures (2), and cranial nerve palsies (1) . All eight patients with 
Toxicity
There was no treatment-related mortality in any of the 28 patients with SLE-related APS who underwent autologous HSCT. Characteristics related to stem cell engraftment, including day of white blood cell and platelet engraftment after stem cell infusion (day 0), platelet and red blood cell transfusion requirements, total number of days spent in hospital, infections during hospitalization, and serious adverse events including need for dialysis and intubation, are described in Table 2 . The mean time to ANC > 500/ul and platelet count > 20,000/ul was day 9 and 12, respectively. The mean hospitalized stay for HSCT was 20 days. The only patients that required dialysis were already on dialysis (1 peritoneal dialysis, 2 hemodialysis) prior to enrollment into study. One patient required intubation secondary to pulmonary edema for one day. Peri-transplant related infections included: bacteremia (4 patients), candida fungemia (1 patient), candida peritonitis (1 patient), bacterial pneumonia (1 patient), bacterial urinary tract infection (2 patients), clostridium difficile colitis (1 patient), salmonella colitis (1 patient), cytomegalovirus (CMV) antigenemia (1 patient), and mucocutaneous herpes simplex (2 patients).
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Anti-phospholipid antibodies
Nineteen patients with SLE-related APS (eleven from definite APS group and eight from probable APS group) were positive for LA and/or ACLA at the time of entry into study.
Lupus anticoagulant
Ten patients had LA at the enrollment: 7 patients with definite APS, and 3 patients with 
ACLA IgG antibodies
ACLA IgM antibodies
Of eleven ACLA IgM-positive patients, antibody serial measurements up to 28 months (median 12 months) post-HSCT showed normalization of titers in nine (82%) (Figure 2 ).
In the definite APS group, 6 patients were ACLA IgM-positive pre-transplant. Five of them had normalization of titers (84%). One woman demonstrated elevated ACLA IgM titer at 9 months corresponding to persistence of active SLE. In probable APS group, 5 patients were positive for ACLA IgM pre-HSCT and 4 of them (80%) seroconverted to negative. One patient's IgM reappeared together with high IgG titer followed by seizure reoccurrence at 24 months. Three patients (all from definite APS group) with history of elevated ACLA IgM titers in the past but normal pre-transplant remained seronegative with a median 12 months follow up. (months)
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Twenty-two of 28 patients with APS were on anticoagulation (warfarin, lovenox, aspirin and/or plavix) when referred for transplant. Eighteen of these 22 patients (82%) were discontinued from anticoagulation immediately to 30 months post-transplant (mean of 6 months, median 4 months) ( Table 3) For personal use only. on September 24, 2017. by guest www.bloodjournal.org From stopping anticoagulation. Four patients who had discontinued anticoagulation had rethrombosis. Of note, their anticoagulation was stopped early, at a mean interval of 3 months (median 3 months) post-HSCT. One patient developed a splenic infarct (found accidentally by imaging study) and an upper extremity DVT at 10 months after HSCT with elevated ACLA IgM titer. Another patient who developed a saphenous vein graft thrombosis 10 months after transplant, also showed recurrence of LA (which was negative at 3 months post-HSCT when LMWH was discontinued). Of two patients who developed upper extremity DVT due to indwelling central lines, one remained negative for LA, and second was not retested for APLA after HSCT. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
Non-thrombotic APS-related manifestations
There was no difference in APLA-associated symptoms between those who did not meet Sapporo criteria and those who did. In all 28 patients with APS, the type and number of pre-HSCT non-thrombotic APS associated features included: LSE (2), LR(3), calciphylaxis (2), thrombocytopenia (6), seizures (6), cranial nerve palsies (4), myelitis / transverse myelitis (4), ataxia (1), hallucinations (1), intractable headaches (2), multiple TIA(s) (1), silent CVA(s) (1) ( Table 1) . Post-HSCT, most non-thrombotic APS-related symptoms improved or stabilized (myelitis (3), ataxia (1), cranial nerve palsies (4), hallucinations (1), headache (1), calciphylaxis (2), LR (1) and have not recurred (LSE (2), TIA (1), seizures (5), thrombocytopenia (3) ( Table 3 ). One patient with intractable headache and two with LR continue to manifest these APS features. One patient developed new headache at 48 months post-HSCT. Three patients developed thrombocytopenia at 3, 5 and 12 months post-transplant. One patient relapsed with seizure at 24 months post-HSCT. One patient had recurrent transverse myelitis attack at 9 months after the stem cell transplant.
Outcome of SLE
Twenty-one patients of those 28 with APS entered remission of SLE after HSCT (75%).
Nine patients (32%) were able to discontinue all immunosuppressive medications from immediately to 13 months post-transplant (median 12 months) and stayed in remission from 12 to 66 months (median 24 months) since stopping immunosuppression ( Table 3) .
Analysis of antinuclear antibody (ANA) in the 28 patients with SLE-related APS demonstrates a statistically significant decrease in mean of ANA titers after HSCT ( Figure 3 ). 
Correlation between post-HSCT APLA versus thrombotic events, non-thrombotic APSassociated manifestations and SLE disease activity
Detailed description of post-transplant APLA results, thrombotic events, associated APS features, outcome of SLE, and anticoagulation and immunosuppression history in each APS patient is shown in Table 3 . Figure 4 illustrates distribution of all positive APLA cases (5) , recurrent thrombotic events (5), persistent and/or relapsed non-thrombotic APS-related manifestations (9) and active SLE disease (8) 
Discussion
Our study is consistent with previous reports showing a high frequency of APLA, LA and/or ACLA, and secondary APS in patients with SLE. [23] [24] [25] [26] [27] Controversy still exists as to which specific antibody, isotype, or their combination correlates with clinical deterioration. 37, 38 In addition to IgG and IgM ACLA, some studies have found significant associations between persistently elevated ACLA IgA titers and APS manifestaions such as progressive neurocognitive dysfunction. 9, 39 Since IgA ACLA isotype is not currently part of the Sapporo criteria for APS, we did not measure ACLA IgA levels in our patients. More recently, beta2-glycoprotein I (b2-GPI) has been reported to be the clinically important APLA antigen associated with thrombosis in patients with autoimmune disease. [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] However, in most laboratories, antibodies detected during standard ELISA testing are not specific for b2-GPI. [50] [51] [52] Differentiation of "specific" anti-b2-GPI antibodies was not performed in our study which was started 7 years ago, before the association of APS with b2-GPI.
Currently, Sapporo criteria do not include associated APS features (LR, LSE, thrombocytopenia, certain CNS manifestations) as part of the definition of APS. 1, 2 Our study is unique in respect to SLE population studied since all the patients entering the study have had severe and refractory SLE and a large proportion of them have had significant histories of thromboembolic events as well as APS-related manifestations.
Therefore, in addition to patients with definite APS we analyzed another group of patients who did not fulfill the Sapporo criteria, defined as probable APS. Pre-transplant, these patients demonstrated positive APLA and had APS-related manifestations without history of thrombosis. We observed similar effectiveness of HSCT on APS-related manifestations between patient groups with definite and probable APS. However, none of the patients in probable APS group experienced a thrombotic event after HSCT.
Patients with APS and positive APLA at study enrollment generally became and remained negative for antibodies following HSCT. Of eight patients who were LApositive pre-HSCT, only two demonstrated reappearance of lupus anticoagulant. Of fourteen patients who were ACLA positive at pre-HSCT enrollment, three patients manifested elevated ACLA titers after HSCT. Recurrent ACLA antibodies were of same isotype (LA, ACLA IgG and /or IgM) compared to pre-transplant. Patients with APS who were APLA negative at pre-transplant enrollment demonstrated sustained seronegativity when followed for up to 78 months after HSCT except one patient in whom recurrence of APLA occurred in relation to pregnancy, an event associated with flare or initiation of SLE 53, 54 .
With the exception of one patient with catheter-related thrombosis and one patient with recurrent coronary artery occlusions, no patient who maintained APLA seronegativity developed post-transplant thromboembolic events. In contrast, relapsed LA or ACLA tended to correlate with recurrent thrombotic and / or APS-related events. Of the two patients with relapsed LA, one experience a saphenous vein graft thrombosis concurrently with reversion to seropositivity. Of three patients with elevated ACLA following HSCT, one had a seizure and another developed a splenic infarct, upper extremity DVT, and thrombocytopenia.
Non-parametric statistical analysis showed significant correlation between ACLA/LA relapse, SLE recurrence, and APS associated symptoms. The highest correlation was between active SLE and associated APS manifestations (T = 0.79, p<0.05), less so between positive APLA and associated APS manifestations (T = 0.56, p<0.05).
Thrombotic events had a moderate correlation with SLE activity (T = 0.44, p<0.05) and APLA positivity (T = 0.41, p<0.05). Active SLE disease correlated with both recurrent thrombotic events and associated APS manifestations, more so than seropositive APLA. This finding supports multiple previous observations that ongoing inflammation in lupus patients is involved in thrombogenesis, either by altering coagulation pathways in the presence of APLA or by another procoagulant action of SLE per se, other than that related to APLA. 50, 55 Autologous HSCT in patients with SLE appears to be effective therapy in eliminating APLA in the majority of APS patients, improving or stabilizing APS-related manifestations, and preventing further thromboembolic events. HSCT allowed the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From additional advantage of discontinuing anticoagulant therapy thereby preventing potential serious bleeding complications associated with prolonged anticoagulation. In developing autologous HSCT studies for SLE, APS was initially considered a possible contraindication to treatment due to lack of response of APS to immune suppression and due to risk of thrombosis and /or bleeding during the transplant. These data indicate that HSCT may be performed safely in patients with APLA / APS without peri-transplant bleeding despite use of low molecular weight heparin anticoagulation throughout the transplant. Post-transplant APS control with disappearance of APLA and discontinuation of chronic anticoagulation in the majority of patients is a strong indication of the efficacy of this therapy for SLE-related APS. Whether autologous HSCT will result in long-term cure of some APS patients is not currently known.
Our treatment induced SLE remission in 75% of APS population. Similar remission rates as well as significant decrease in ANA titers were observed in the whole group of 46 patients with SLE treated by HSCT (data not shown, manuscript in preparation). None of the patients without definite or probable APS before the transplant developed APS as a manifestation of relapse after HSCT.
There are several limitations to the current study. First, ACLA results were obtained in two different laboratories, and even if currently more standardized, variability in commercial ELISA kits is still a problematic issue. 56 Second, the last few patients had relatively short period of follow-up, and durability of results and antibody and clinical relapse rate still needs to be determined. Third, we did not have a control group, a significant argument considering common fluctuations in APLA. Fourth, anti-b2-GPI antibody which at the start of this study (7 years ago) was not available should be followed in future trials.
In summary, of 46 patients with severe and refractory SLE, the prevalence of APS was 61%. Ten patients had positive LA, and fourteen patients had high titers of ACLA IgG and/or IgM immediately before the stem cell transplant. LA disappeared in 75% of evaluable patients after HSCT. 71% had normalization of ACLA IgG titers, and 82%
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From became and remained negative for ACLA IgM. 82% of patients with SLE-related APS discontinued anticoagulation at median of 4 months after the transplant; 78% of them remained thrombosis-free for up to 78 months (median 15 months) after HSCT. Highdose chemotherapy and autologous hematopoietic stem cell transplantation may be an efficient treatment modality in eliminating APLA and preventing or diminishing thrombotic complications and APS-related manifestations in patients with SLE-related APS.
